<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02347332</url>
  </required_header>
  <id_info>
    <org_study_id>L00070 IN 309 F0</org_study_id>
    <nct_id>NCT02347332</nct_id>
  </id_info>
  <brief_title>Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer</brief_title>
  <official_title>Phase III Study of IV Vinflunine in Combination With Methotrexate Versus Methotrexate Alone in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients relapsing after platinum-based therapy, few data are available. The current use
      of cetuximab associated with radiotherapy in localized disease and associated with
      platinum-based chemotherapy in the first-line setting stresses the need for new therapeutic
      options at later stages of SCCHN.Vinca-alkaloids demonstrated activity in SCCHN. Vinflunine
      demonstrated superior antitumour activity to vinorelbine in preclinical animal models. Recent
      preliminary phase I results of the vinflunine plus methotrexate combination in SCCHN, based
      on a clinical review, show encouraging antitumour activity and an acceptable safety profile.
      Therefore the combination of vinflunine and methotrexate appears a promising salvage regimen
      after platinum failure.

      The present study has been designed as a multicenter, randomised phase III study which will
      compare the combination of IV vinflunine with methotrexate to methotrexate alone in SCCHN
      patients having failed platinum-based therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed to compare the OS of VFL plus MTX versus MTX alone in patients with
      SCCHN who had failed platinum-based chemotherapy.

      The trial was designed in accordance with current standards used routinely in oncology phase
      III trials and used established methods of assessment. The RECIST (version 1.1) and NCI CTCAE
      (version 3.0) guidelines are internationally recognised methods for assessing efficacy and
      tolerance, respectively.

      The patient population was appropriate for this type of phase III study and included adult
      patients with recurrent and/or metastatic squamous cell carcinoma of the oral cavity,
      oropharynx, hypopharynx or larynx, who had received prior chemotherapy regimens with
      documented progression. This population of patients was considered appropriate to meet the
      study objectives.

      Recent preliminary phase I results of the VFL plus MTX combination in SCCHN, reported in a
      clinical review, showed encouraging antitumour activity and an acceptable safety profile A
      number of chemotherapy agents have been reported as having single-agent activity in SCCHN.
      However, reliable evidence of efficacy in the second-line setting is lacking, and there is
      currently no established standard of care. MTX used alone as the reference regimen at a dose
      of 40 mg/m2/week can be considered as the best available evidence-based option. Also, other
      trials using this comparator have demonstrated that it is generally accepted as a reasonable
      choice, and is often used in general practice.

      The efficacy and safety assessments employed in this study are standard measures routinely
      used in studies of this type
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 25, 2014</start_date>
  <completion_date type="Actual">November 23, 2018</completion_date>
  <primary_completion_date type="Actual">October 20, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival in the ITT Population (Months)</measure>
    <time_frame>Participants will be followed till death (if they are not lost for follow-up), an expected average of 7.5 months</time_frame>
    <description>Time from randomization to the date of death or last follow-up. The survival duration of patients still alive, was censored at the date of last contact or last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>an expected average of 4 months</time_frame>
    <description>Time measured from the date of randomisation until date of progression or death from any cause (whichever came first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The objective response is defined as the best response designation recorded across all time points from the date of randomisation until disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>30 months</time_frame>
    <description>Percentage of best overall responses CR, PR and SD in the analysed population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>30 months</time_frame>
    <description>Duration of objective response will be measured for responders (CR+PR) from the time for CR or PR until the 1st date of documentation of recurrent or progressive disease or the date of death any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">459</enrollment>
  <condition>Recurrent or Metastatic Head and Neck Carcinoma</condition>
  <arm_group>
    <arm_group_label>Vinflunine plus methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vinflunine IV 280 mg/m² Day 1 plus methotrexate IV 30 mg/m² Day 1 and Day 8 every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>methotrexate IV 40 mg/m² Day 1, 8 and 15 every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinflunine</intervention_name>
    <arm_group_label>Vinflunine plus methotrexate</arm_group_label>
    <other_name>JAVLOR</other_name>
    <other_name>VFL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>Methotrexate</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed recurrent and/or metastatic squamous cell
             carcinoma

          -  Documented progressive disease after chemotherapy for locoregionally advanced or
             recurrent/metastatic SCCHN which included a platinum derivative

          -  Measurable or non measurable disease

          -  adequate haematological, hepatic and renal functions

          -  WHO performance status &lt; 1

        Exclusion Criteria:

          -  Nasopharyngeal carcinoma

          -  History of brain or leptomeningeal involvement

          -  Albumin level &lt; 35 g/L

          -  Patients with weight loss ≥ 5% within the last 3 months

          -  Grade &gt; 2 peripheral neuropathy at study entry

          -  &quot;Third space&quot; fluids (pleural effusion, ascites, massive edema)

          -  Prior treatment with vinca-alkaloids and methotrexate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zahida Issiakhem, MD</last_name>
    <role>Study Director</role>
    <affiliation>Institut de Recherche Pierre Fabre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Recherche Pierre Fabre</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2015</study_first_posted>
  <results_first_submitted>June 26, 2018</results_first_submitted>
  <results_first_submitted_qc>February 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 4, 2019</results_first_posted>
  <last_update_submitted>February 13, 2019</last_update_submitted>
  <last_update_submitted_qc>February 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vinflunin</keyword>
  <keyword>Vinflunin + Methotrexate</keyword>
  <keyword>Metastatic Squamous Cell Carcinoma of the Head and Neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 5, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT02347332/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT02347332/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>5 patients in VFL+MET arrm and 2 patients in MET arm did not receive any treatement. These patients excluded from safety population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vinflunine Plus Methotrexate</title>
          <description>Vinflunine IV 280 mg/m² day 1 plus methotrexate IV 30 mg/m² Day 1 and Day 8 every 3 weeks
Vinflunine</description>
        </group>
        <group group_id="P2">
          <title>Methotrexate</title>
          <description>Methotrexate IV 40 mg/m² days 1, 8 and 15 every 3 weeks
Methotrexate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="229"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">6 patients: suicide(1), unknown cause(5 - 4 at home +1 in city hospital).</participants>
                <participants group_id="P2" count="0">6 patients: unknown cause(2home), PDsuspect(1home+1hosp), sudden death(1home), hypercapnie(1hosp).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="229"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="159"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death (Unknown, Various reasons)</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol requirement</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Switch Post-Trial program</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vinflunine Plus Methotrexate</title>
          <description>Vinflunine IV 280 mg/m² day 1 plus methotrexate IV 30 mg/m² Day 1 and Day 8 every 3 weeks
Vinflunine</description>
        </group>
        <group group_id="B2">
          <title>Methotrexate</title>
          <description>Methotrexate IV 40 mg/m² days 1, 8 and 15 every 3 weeks
Methotrexate</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="230"/>
            <count group_id="B2" value="229"/>
            <count group_id="B3" value="459"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="230"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="357"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="230"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Austria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="230"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belarus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="230"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="230"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="230"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="230"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="230"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="230"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="230"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="230"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="230"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="230"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="230"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="230"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="230"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="230"/>
                    <count group_id="B2" value="229"/>
                    <count group_id="B3" value="459"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival in the ITT Population (Months)</title>
        <description>Time from randomization to the date of death or last follow-up. The survival duration of patients still alive, was censored at the date of last contact or last follow-up.</description>
        <time_frame>Participants will be followed till death (if they are not lost for follow-up), an expected average of 7.5 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Vinflunine Plus Methotrexate</title>
            <description>Vinflunine IV 280 mg/m² day 1 plus methotrexate IV 30 mg/m² Day 1 and Day 8 every 3 weeks
Vinflunine</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate</title>
            <description>Methotrexate IV 40 mg/m² days 1, 8 and 15 every 3 weeks
Methotrexate</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival in the ITT Population (Months)</title>
          <description>Time from randomization to the date of death or last follow-up. The survival duration of patients still alive, was censored at the date of last contact or last follow-up.</description>
          <population>ITT population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="5.7" upper_limit="8.4"/>
                    <measurement group_id="O2" value="6.8" lower_limit="6.1" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8329</p_value>
            <p_value_desc>Threshold significance value p&lt;0.05</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Time measured from the date of randomisation until date of progression or death from any cause (whichever came first)</description>
        <time_frame>an expected average of 4 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Vinflunine Plus Methotrexate</title>
            <description>Vinflunine IV 280 mg/m² day 1 plus methotrexate IV 30 mg/m² Day 1 and Day 8 every 3 weeks
Vinflunine</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate</title>
            <description>Methotrexate IV 40 mg/m² days 1, 8 and 15 every 3 weeks
Methotrexate</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Time measured from the date of randomisation until date of progression or death from any cause (whichever came first)</description>
          <population>ITT</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.6" upper_limit="3.3"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.1" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3576</p_value>
            <p_value_desc>Threshold significance value p&lt;0.05</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>The objective response is defined as the best response designation recorded across all time points from the date of randomisation until disease progression.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vinflunine Plus Methotrexate</title>
            <description>Vinflunine IV 280 mg/m² day 1 plus methotrexate IV 30 mg/m² Day 1 and Day 8 every 3 weeks
Vinflunine</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate</title>
            <description>Methotrexate IV 40 mg/m² days 1, 8 and 15 every 3 weeks
Methotrexate</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>The objective response is defined as the best response designation recorded across all time points from the date of randomisation until disease progression.</description>
          <units>Percent of participants</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" lower_limit="13.1" upper_limit="23.4"/>
                    <measurement group_id="O2" value="14.8" lower_limit="10.5" upper_limit="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.467</p_value>
            <p_value_desc>Threshold significance value p&lt;0.05</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate</title>
        <description>Percentage of best overall responses CR, PR and SD in the analysed population</description>
        <time_frame>30 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vinflunine Plus Methotrexate</title>
            <description>Vinflunine IV 280 mg/m² day 1 plus methotrexate IV 30 mg/m² Day 1 and Day 8 every 3 weeks
Vinflunine</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate</title>
            <description>Methotrexate IV 40 mg/m² days 1, 8 and 15 every 3 weeks
Methotrexate</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate</title>
          <description>Percentage of best overall responses CR, PR and SD in the analysed population</description>
          <units>% patients</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" lower_limit="44.2" upper_limit="57.5"/>
                    <measurement group_id="O2" value="46.3" lower_limit="39.7" upper_limit="53.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.243</p_value>
            <p_value_desc>Threshold significance value p&lt;0.05</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of objective response will be measured for responders (CR+PR) from the time for CR or PR until the 1st date of documentation of recurrent or progressive disease or the date of death any cause.</description>
        <time_frame>30 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Vinflunine Plus Methotrexate</title>
            <description>Vinflunine IV 280 mg/m² day 1 plus methotrexate IV 30 mg/m² Day 1 and Day 8 every 3 weeks
Vinflunine</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate</title>
            <description>Methotrexate IV 40 mg/m² days 1, 8 and 15 every 3 weeks
Methotrexate</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of objective response will be measured for responders (CR+PR) from the time for CR or PR until the 1st date of documentation of recurrent or progressive disease or the date of death any cause.</description>
          <population>ITT</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="2.5" upper_limit="5.6"/>
                    <measurement group_id="O2" value="4.2" lower_limit="2.7" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6289</p_value>
            <p_value_desc>Threshold significance value p&lt;0.05</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years 6 months 29 days. 5 subjects in the Vinflunine + Methotrexate arm and 2 patients in the Methotrexate arm did not receive any treatment. These patients were thus excluded from the safety population.The safety population consisted of all patients randomized and treated.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vinflunine Plus Methotrexate</title>
          <description>Vinflunine IV 280mg/m2 Day1 plus Methotrexate IV 30mg/m2 on Day 1 and Dy 8 every 3 cycles
Vinflunine</description>
        </group>
        <group group_id="E2">
          <title>Methotrexate</title>
          <description>Methotrexate IV 40 mg/m² days 1, 8 and 15 every 3 weeks
Methotrexate</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="185" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="194" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Tumour Haemorrage</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Tumour Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="211" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="213" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="219" subjects_affected="89" subjects_at_risk="225"/>
                <counts group_id="E2" events="190" subjects_affected="71" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="245" subjects_affected="82" subjects_at_risk="225"/>
                <counts group_id="E2" events="147" subjects_affected="56" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="93" subjects_affected="32" subjects_at_risk="225"/>
                <counts group_id="E2" events="102" subjects_affected="38" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="19" subjects_at_risk="225"/>
                <counts group_id="E2" events="65" subjects_affected="24" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="163" subjects_affected="56" subjects_at_risk="225"/>
                <counts group_id="E2" events="42" subjects_affected="25" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="117" subjects_affected="53" subjects_at_risk="225"/>
                <counts group_id="E2" events="158" subjects_affected="64" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="66" subjects_affected="36" subjects_at_risk="225"/>
                <counts group_id="E2" events="40" subjects_affected="23" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="37" subjects_affected="26" subjects_at_risk="225"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="34" subjects_affected="23" subjects_at_risk="225"/>
                <counts group_id="E2" events="23" subjects_affected="13" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="18" subjects_at_risk="225"/>
                <counts group_id="E2" events="45" subjects_affected="13" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="225"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="181" subjects_affected="62" subjects_at_risk="225"/>
                <counts group_id="E2" events="137" subjects_affected="54" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="26" subjects_at_risk="225"/>
                <counts group_id="E2" events="53" subjects_affected="27" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="52" subjects_affected="24" subjects_at_risk="225"/>
                <counts group_id="E2" events="53" subjects_affected="27" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="48" subjects_affected="19" subjects_at_risk="225"/>
                <counts group_id="E2" events="55" subjects_affected="17" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="248" subjects_affected="69" subjects_at_risk="225"/>
                <counts group_id="E2" events="150" subjects_affected="63" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="49" subjects_affected="17" subjects_at_risk="225"/>
                <counts group_id="E2" events="28" subjects_affected="10" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="47" subjects_affected="12" subjects_at_risk="225"/>
                <counts group_id="E2" events="227" subjects_affected="15" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="26" subjects_affected="11" subjects_at_risk="225"/>
                <counts group_id="E2" events="74" subjects_affected="28" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="59" subjects_affected="27" subjects_at_risk="225"/>
                <counts group_id="E2" events="45" subjects_affected="23" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="40" subjects_affected="14" subjects_at_risk="225"/>
                <counts group_id="E2" events="30" subjects_affected="12" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="58" subjects_affected="20" subjects_at_risk="225"/>
                <counts group_id="E2" events="29" subjects_affected="12" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="225"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="26" subjects_affected="18" subjects_at_risk="225"/>
                <counts group_id="E2" events="34" subjects_affected="18" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="42" subjects_affected="24" subjects_at_risk="225"/>
                <counts group_id="E2" events="27" subjects_affected="10" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="32" subjects_affected="14" subjects_at_risk="225"/>
                <counts group_id="E2" events="52" subjects_affected="22" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sponsor ended recrutement and decided to limit analysis of efficacy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Zahida Issiakhem, Clinical Development Physician</name_or_title>
      <organization>Institut de Recherche Pierre Fabre, Toulouse France</organization>
      <phone>+33 5 34 50 61 71</phone>
      <email>zahida.issiakhem@pierre-fabre.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

